The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients. Enhertu was approved for the treatment of ...

The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

Secretary of State for Science, Innovation and Technology Rt Hon Peter Kyle and Minister of State for Science, Research and ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...